Company

Immuron Ltd

ASX:IMC

Immuron Ltd (ASX:IMC, NASDAQ:IMRN) is focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

71 stories · page 1 of 4

Pharma & Biotech

Immuron turns in strong performance for Travelan® in September quarter, expands globally

By Proactive 15/10/2024

Pharma & Biotech

Immuron making inroads into the international market with flagship assets Travelan and IMM-529

By Proactive 11/10/2024

Pharma & Biotech

Immuron welcomes NMRC results for campylobacter in controlled human infection model study

By Proactive 07/10/2024

Pharma & Biotech

Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529

By Proactive 06/09/2024

Pharma & Biotech

Immuron nets A$3.5 million in funding from US Department of Defense for Travelan® research

By Proactive 16/08/2024

Pharma & Biotech

Immuron "trading at substantial discount to valuation": Pitt Street Research

By Proactive 01/08/2024

Pharma & Biotech

Immuron's innovations in gastrointestinal immunotherapy paying off commercially at home and abroad

By Proactive 17/07/2024

Pharma & Biotech

Immuron achieves record sales in FY2024 with 174% growth across markets

By Proactive 15/07/2024

Pharma & Biotech

Immuron secures around US$2 million in funding after lodging Form F-3 and ATM prospectus with US SEC

By Proactive 03/07/2024

Pharma & Biotech

Immuron files pre-investigational new drug US FDA application for superbug fighting IMM-529

By Proactive 02/07/2024

Pharma & Biotech

Immuron marks surge in Travelan® sales on eve of entry into US via Walmart.com

By Proactive 10/04/2024

Pharma & Biotech

Immuron to join exclusive list of ASX biotechs says Pitt Street Research

By Proactive 22/03/2024

Pharma & Biotech

Immuron doubles on promising Travelan® Phase 2 results, advancing to Phase 3 trials in US

By Proactive 07/03/2024

Pharma & Biotech

Immuron's antibody platform pioneers new approach to gastro-intestinal disease

By Proactive 21/02/2024

Pharma & Biotech

Immuron achieves record Travelan® sales as travel picks up

By Proactive 13/02/2024

Pharma & Biotech

Immuron’s valuation reiterated by Pitt Street Research following progress in clinical trials

By Proactive 06/02/2024

Pharma & Biotech

Immuron makes steady progress in clinical trials as Travelan sales grow

By Proactive 04/02/2024

Pharma & Biotech

Immuron chalks up stellar half-year Travelan sales as travel returns to pre-pandemic levels

By Proactive 16/01/2024

Pharma & Biotech

Immuron enrols first patients in Campylobacter Challenge clinical study

By Proactive 05/12/2023

Pharma & Biotech

Immuron receives bull case valuation of A$0.35 from Pitt Street Research

By Proactive 01/11/2023